SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

InNexus Biotechnology Inc. (IXSBF)

IXSBF RSS Feed
Add IXSBF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/29/2016 3:46:20 PM - Followers: 4 - Board type: Free - Posts Today: 0

InNexus Biotechnology CEO to Present at BioContactQuebec 2008

BRITISH COLUMBIA, Canada, Sep. 29, 2008 (Canada NewsWire via COMTEX) --
<<
-- Receives Recognition in Two Leading Industry Publications --

>>

InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces Jeff Morhet, CEO and Chairman, to present during BioContactQuebec 2008. The company also announces the featuring of Mr. Morhet in two leading publications, Genetic Engineering & Biotechnology News and The PharmaVoice List of Top 100 in Life Sciences.
During BioContactQuebec 2008, InNexus' CEO will present on Thursday, October 2nd at 2:30-3:00 PM EDT on the Salle Laval at the Chateau Frontenac, Quebec. The presentation will include a company overview and information about InNexus' unique business strategy, its DXL(TM) technology platform and upcoming company milestones. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the symposium.

Also announced, the most recent edition of Genetic Engineering & Biotechnology News features InNexus CEO Morhet in the article, Peptide Drugs Becoming More Prevalent, where he discusses the pharmaceutical industry and outlines InNexus' DXL(TM) antibody enhancement technology platform. http://www.genengnews.com/articles/chitem.aspx?aid=2580.

The company also announced Mr. Morhet has also been named to PharmaVOICE's list of the "100 Most Inspiring People in the Life Sciences", July/August Edition. The publication illustrates those individuals who think outside the box, pioneering new paths to success and inspire their colleagues in the industry. http://www.pharmavoice.com

<<
About BioContactQuebec 2008
>>

BioContactQuebec 2008 is a biopharmaceutical partnership symposium gathering over 1200 participants and more than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as cancer, immunology and inflammation.
<<
About InNexus
>>

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in- house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

SOURCE: InNexus Biotechnology Inc

SureTrader
Interactive Brokers Advertisement
IXSBF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PostSubject
#17   Eggsackly--a cheap way to make shorts sweat, and ernie44 12/29/16 03:46:20 PM
#16   All SEC suspended stocks can trade on the Renee 12/29/16 03:21:57 PM
#15   susp. suspended--traded 40000 today glta ernie44 12/29/16 01:07:12 PM
#14   IXSBF SEC Suspension: Renee 03/02/15 09:56:45 AM
#13   We have movement $$$$$$ redamatik 09/25/14 12:00:55 AM
#12   free money is always good and yes this mrmotogp 02/11/11 10:49:14 AM
#11   $100,000. ain't shit and this co. is a POS Scheid27 02/11/11 04:33:53 AM
#10   InNexus Biotechnology Awarded Federal Grant mrmotogp 11/08/10 10:50:14 AM
#9   InNexus Announces Discovery of Novel Protein for AMD mrmotogp 06/29/10 09:46:50 AM
#8   InNexus Biotechnology Signs Collaboration Agreement with the National mrmotogp 06/01/10 04:23:34 PM
#7   2:39 PM ET 3/23/10 / BusinessWire mrmotogp 03/23/10 03:25:56 PM
#6   InNexus Biotechnology Inc. (TSX.V: IXS) (www.ixsbio.com), a drug mrmotogp 01/06/10 10:56:03 AM
#5   InNexus And XERIS Announce Research Collaboration mrmotogp 12/10/09 12:31:48 PM
#4   InNexus Bio Issues a Shareholder Update mrmotogp 12/08/09 10:18:38 AM
#3   InNexus Announces Business Development Initiative mrmotogp 08/05/09 04:25:00 PM
#2   well beaten down indeed - atleast volume has mrmotogp 07/30/09 02:09:31 PM
#1   Decent news for this company this morning, been jonno1 07/10/09 09:45:56 AM
PostSubject